Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

ARA-290 Dosage Guide: How Much Should You Take? (2026)

ARA-290 Dosage Guide: How Much Should You Take? (2026) Key Takeaways Standard Dosage Range: ARA-290 is typically administered at doses ranging from 4 mg to 8 mg, depending on the therapeutic goal and patient response. Administration Method: Primarily administe

ARA-290 Dosage Guide: How Much Should You Take? (2026)

Key Takeaways

Standard Dosage Range: ARA-290 is typically administered at doses ranging from 4 mg to 8 mg, depending on the therapeutic goal and patient response.

Administration Method: Primarily administered via subcutaneous injection due to its bioavailability and targeted delivery.

Typical Cycle Length: Treatment cycles can vary from 4 to 12 weeks, with adjustments based on individual response and clinical objectives.

Regulatory Status: ARA-290 is not FDA-approved for therapeutic use; it is available for research purposes only.

Medical Supervision: Due to its research status, ARA-290 should be used under the guidance of a qualified healthcare provider.

How ARA-290 Works in the Body

ARA-290 is a synthetic peptide derived from the B-helix domain of erythropoietin, designed to interact with the EPOR–CD131 receptor complex. This interaction activates the innate repair receptor (IRR) pathway, promoting tissue protection without stimulating erythropoiesis. The specificity of ARA-290 for this receptor complex is crucial in its therapeutic applications, particularly in modulating inflammatory responses and protecting neural tissues.

The pharmacokinetic properties of ARA-290, such as its half-life and bioavailability, significantly impact dosing decisions. ARA-290 exhibits a relatively short half-life, necessitating frequent administration to maintain therapeutic levels. Its bioavailability is optimal when administered subcutaneously, allowing for direct absorption into the bloodstream.

Clinical studies have explored ARA-290's efficacy in various conditions. For instance, a study published in Molecular Medicine (PMID 25387363) demonstrated its potential in improving metabolic control and neuropathic symptoms in type 2 diabetes patients. Similarly, research published in Molecular Pain (PMID 24529189) highlighted its ability to provide long-term relief of neuropathic pain.

"ARA-290, a nonerythropoietic peptide engineered from erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection." — Molecular Medicine (PMID 25387363)

Standard ARA-290 Dosage Ranges (By Form)

Subcutaneous Administration

Dosage Range: 4 mg to 8 mg per administration

Frequency: Typically administered once daily

Bioavailability: High, due to direct absorption into the bloodstream

Commonality: Subcutaneous injection is the preferred form due to its efficacy and ease of use.

Intramuscular Administration

Dosage Range: Similar to subcutaneous, but less commonly used

Frequency: Once daily or as directed by a healthcare provider

Bioavailability: Slightly lower than subcutaneous administration

Oral and Other Forms

Currently, ARA-290 is primarily available as a lyophilized powder for research use, with subcutaneous injection being the most common administration route. Oral and other forms are not widely utilized due to reduced bioavailability and lack of clinical validation.

ARA-290 Dosage by Use Case

Neuropathic Pain Management

Typical Dosage Range: 4 mg to 6 mg subcutaneously

Administration Method: Subcutaneous injection

Cycle Length: 8 to 12 weeks

Study Reference: A study in Molecular Pain (PMID 24529189) supports its use for neuropathic pain relief.

Inflammation Modulation

Typical Dosage Range: 4 mg to 8 mg subcutaneously

Cycle Length: 4 to 8 weeks

Study Reference: Research in Brain, Behavior, and Immunity (PMID 34343617) explores its role in modulating inflammation.

Metabolic Control in Diabetes

Typical Dosage Range: 4 mg subcutaneously

Cycle Length: 12 weeks

Study Reference: Molecular Medicine (PMID 25387363) highlights its efficacy in metabolic control.

How Long Should You Take ARA-290?

The duration of ARA-290 therapy depends on the specific therapeutic goal and individual patient response. Typical treatment cycles range from 4 to 12 weeks. During the initial week, patients may begin to notice subtle improvements, with more pronounced effects emerging between weeks 2 to 4. By week 6 and beyond, many patients report significant symptom relief.

Tapering off ARA-290 is generally not required due to its short half-life. However, discontinuation should be managed by a healthcare provider to monitor any potential return of symptoms.

Administration Protocol: How to Take ARA-290

Injection Technique

Needle Gauge: Use a 27-30 gauge needle for subcutaneous injections.

Injection Sites: Rotate between the abdomen, thigh, and upper arm to prevent tissue damage.

Rotation Schedule: Rotate injection sites daily to minimize local irritation and improve absorption.

Storage Requirements

Temperature: Store lyophilized powder at 2-8°C (36-46°F).

Light Sensitivity: Protect from light to maintain stability.

Reconstituted Stability: Use reconstituted solution within 24 hours if stored at room temperature.

Reconstitution Instructions

For detailed reconstitution instructions, refer to our reconstitution guide.

Administration Process

Preparation: Wash hands and gather all necessary supplies.

Reconstitution: Mix the lyophilized powder with the appropriate diluent.

Injection: Clean the injection site with an alcohol swab, pinch the skin, and inject at a 45-degree angle.

Post-Injection: Apply gentle pressure with a cotton ball or gauze.

Stacking ARA-290 for Better Results

ARA-290 and BPC-157

Combination: ARA-290 (4 mg) with BPC-157 (250 mcg)

Dosing Synergy: Enhances tissue repair and reduces inflammation

Common Protocols: Used in protocols for sports injuries and chronic pain management

Link: BPC-157

ARA-290 and TB-500

Combination: ARA-290 (4 mg) with TB-500 (2 mg)

Dosing Synergy: Promotes healing and reduces fibrosis

Common Protocols: Often used in protocols for fibrotic conditions

Link: TB-500

Factors That Affect Your ARA-290 Dosage

Several factors can influence the optimal dosage of ARA-290, including:

Body Weight: Heavier individuals may require higher doses.

Age: Older patients may have altered pharmacokinetics.

Treatment Goals: Specific conditions may dictate different dosing.

Kidney/Liver Function: Impaired function can affect metabolism and clearance.

Other Medications: Potential interactions may necessitate dosage adjustments.

Individual Response: Variability in response requires personalized dosing.

Common Dosing Mistakes to Avoid

Dosing Too High/Too Low: Follow prescribed dosages to avoid adverse effects or suboptimal efficacy.

Inconsistent Timing: Administer at the same time daily to maintain stable blood levels.

Wrong Injection Site: Use appropriate sites to optimize absorption.

Not Accounting for Regulatory Status: Remember that ARA-290 is for research only.

Poor Storage/Handling: Store and handle properly to maintain peptide integrity.

What the Evidence Does Not Show

While ARA-290 shows promise in preclinical and early clinical studies, there are limitations to the current evidence:

Long-Term Safety Data: Comprehensive long-term studies are lacking.

Human Trials: Most data are from preclinical or early-phase trials.

Dose-Response Data: Limited information on optimal dosing for various conditions.

FAQ — Your Top ARA-290 Dosage Questions Answered

Best time of day to take it? ARA-290 can be administered at any time, but consistency is key. Choose a time that fits your schedule.

What if you miss a dose? If you miss a dose, take it as soon as you remember unless it's close to your next scheduled dose. Do not double up.

Can men and women use the same dose? Yes, dosing is not typically gender-specific but should be personalized based on individual factors.

Can you stack it with other peptides? Yes, ARA-290 is often stacked with peptides like BPC-157 and TB-500 for enhanced effects.

How long until you see results? Results vary, but many patients report improvements within 2-4 weeks.

Do you need to cycle off? Cycling off is generally not required, but follow your healthcare provider's recommendations.

Is a loading dose needed? A loading dose is not typically necessary for ARA-290.

How to adjust dose if side effects occur? Consult your healthcare provider to adjust dosing if side effects are experienced.

Conclusion — Finding the Right Dosage for You

Determining the appropriate ARA-290 dosage involves considering various factors, including therapeutic goals and individual response. It is crucial to work with a healthcare provider to tailor the dosage to your specific needs. For more information on peptides and their applications, explore our peptide encyclopedia and treatment guides.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Dosage information is compiled from published research and clinical protocols. Consult a licensed healthcare provider before starting any peptide therapy. Use our clinic finder to locate a qualified provider near you.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

ARA-290 Dosage, Reconstitution & Mixing Trends

Explore ARA-290 (cibinetide) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. ARA-290 (cibinetide) is an 11-amino-acid peptide derived from a non-erythropoietic helix-B region of erythropoietin, studied for its tissue-protective and anti-inflammatory effects without the red-cell-stimulating activity of EPO. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their ARA-290 reconstitution protocol. 155 ARA-290 reconstitution calculations have been logged by the WPA community. The most common dose entered is 4mg (61 calculations). The median dose across all sessions is 2mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (96 sessions). The most common dosing frequency is daily (7x/week) (14 logged protocols), followed by 3x/week (8). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.
02

Question drills

Open a question for its connected answer.

01What If the Reconstituted Solution Looks Cloudy or Contains Particles?+

Discard the vial immediately. Do not inject cloudy or particulate-containing solutions under any circumstances. Cloudiness indicates either bacterial contamination (if bacteriostatic water was compromised) or peptide aggregation (if temperature excursions occurred). Aggregated peptides lose bioactivity entirely and can trigger inflammatory immune responses at the injection site. Visual clarity is the minimum quality check; however, clear solution does not guarantee full potency if temperature abuse occurred. This is why source quality matters. Research-grade peptides from suppliers like Real Peptides include stability testing and cold-chain shipping verification.

SOURCE / realpeptides.co ↗
02What If I'm Using ARA-290 for Diabetic Neuropathy — Should I Start at 4mg or 8mg?+

Start at 4mg three times weekly. The Diabetes Care 2017 trial showed that 4mg produced meaningful pain reduction (1.8-point NRS decrease) and IENFD stabilisation with minimal injection site reactions (12% incidence). The 8mg cohort had only marginally better pain scores (2.4-point decrease) but 38% injection site reaction rate. Diabetic SFN responds to lower-dose IRR activation because the primary pathology is metabolic (hyperglycemia-driven oxidative stress and advanced glycation end products), not acute neurotoxic injury. If 4mg shows no response after 8 weeks, escalation to 6mg is reasonable, but most diabetic neuropathy patients who respond do so at the 4mg dose.

SOURCE / realpeptides.co ↗
03What If My Calculated Dose Requires 0.05mL But My Syringe Only Marks Down to 10 Units (0.1mL)?+

Reconstitute with double the bacteriostatic water volume to double the injection volume. If the original plan was 2mL water yielding a 0.05mL dose, reconstitute with 4mL instead. The same dose now requires 0.1mL (10 units), which sits exactly on a syringe graduation line. Dilution does not degrade lyophilised peptides stored correctly. ARA-290 remains stable in bacteriostatic water at 2–8°C for 28 days regardless of concentration.

SOURCE / realpeptides.co ↗
04What If I Miss a Scheduled Dose in a Thrice-Weekly Protocol?+

Administer the missed dose as soon as you recognize the gap, then resume the regular schedule without doubling up. ARA-290's short half-life means receptor occupancy drops within 12–18 hours of the last injection, so a 48-hour gap introduces a trough period where signaling pathways disengage. Missing more than two consecutive doses in a neuroprotection study compromises endpoint reliability. Consistent receptor engagement is required for measurable small fibre density improvements.

SOURCE / realpeptides.co ↗